Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow disability progression.

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

“OCREVUS is the first B-cell therapy approved for RMS and PPMS and it’s remarkable to see that after 10 years of treatment, a great majority of RMS patients remain free from disease ...

The approval of Ocrevus Zunovo was widely expected and does not change Briumvi’s long-term outlook, and this week’s data presentations at ECTRIMS by TG Therapeutics further reinforce Briumvi ...

New safety data as of January 2020 will be presented, representing 5,680 patients with RMS and PPMS and 18,218 patient-years of exposure to Ocrevus, across all Ocrevus clinical trials.

Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple ...

Genentech, a member of the Roche Group, today announced that new Ocrevus ® and Enspryng TM data will be presented at the 37th Congress of the European Committee for Treatment and Research in ...

OCREVUS significantly reduced the proportion of people with RMS who experienced Progression Independent of Relapse Activity (PIRA) in a post-hoc analysis compared to Rebif® (interferon-beta 1a).

Ocrevus, known chemically as ocrelizumab, was also approved to treat the more common form of MS known as relapsing-remitting multiple sclerosis (RRMS), and will be available to people within two ...

OCREVUS ZUNOVO prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and OCREVUS ZUNOVOside effects.

By targeting B-cells, Ocrevus takes a new approach in fighting MS. B-cells are the "key policemen" of the immune system that are culprits in MS, Hauser said.

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's officeThis approval is backed by a decade of proven ...